Results 11 to 20 of about 67,505 (283)

Tolerability, Safety, and Pharmacokinetics of Ivermectin After Nasal Application in Healthy Adult Subjects. [PDF]

J Clin Pharmacol
Abstract Nasal epithelium is the site of infection for SARS‐CoV2 viruses, with interactions of the viral spike protein with the ACE2 receptor of the host cell. Molecular docking studies have shown that ivermectin shields the spike protein and thereby prevents binding to ACE2.
Wissel S, Wissel P, Rischer M, Häberlein F, Riethmüller-Winzen H, Häberlein H.   +5 more
europepmc   +2 more sources

Effect of Early Treatment with Ivermectin among Patients with Covid-19

New England Journal of Medicine, 2022
Background The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome ...
Gilmar Reis, E. A. S. M. Silva, D. Silva, L. Thabane, A. C. Milagres, T. S. Ferreira, C. Dos Santos, V. H. Campos, A. M. Nogueira, A. P. F. G. de Almeida, E. D. Callegari, Adhemar D F Neto, L. C. Savassi, M. I. Simplicio, L. B. Ribeiro, Rosemary Oliveira, Ofir Harari, Jamie I. Forrest, Hinda Ruton, S. Sprague, Paula McKay, Christina M. Guo, K. Rowland-Yeo, G. Guyatt, D. Boulware, C. Rayner, E. Mills   +26 more
semanticscholar   +1 more source

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2023
Importance It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19.
S. Naggie, D. Boulware, C. Lindsell, T. Stewart, Alex Slandzicki, Stephen C. Lim, J. Cohen, D. Kavtaradze, Arch Amon, Ahab Gabriel, N. Gentile, G. Felker, D. Jayaweera, M. McCarthy, M. Sulkowski, R. Rothman, Sybil Wilson, Allison Delong, A. Remaly, Rhonda Wilder, S. Collins, S. Dunsmore, S. Adam, F. Thicklin, George Hanna, A. Ginde, Mario Castro, K. McTigue, E. Shenkman, A. Hernandez, W. Vincent, Raina Vincent, Ray Bianchi, Jen Premas, Diana Cordero-Loperena, Evelyn Rivera, Madhu Gupta, Greg Karawan, Carey Ziomek, Joseph Arena, Sonaly DeAlmeida, Soroush Ramin, J. Nataraj, Michael K. Paasche-Orlow, Lori Henault, K. Waite, David Miller, Ginger Brounce, Constance George-Adebayo, Adeolu Adebayo, Jessica Wallan, C. Vogel, Sebastian Munoz, Cassandra Watson, David Singleton, Maria Rivon, Amanda Sevier, Arnold Del Pilar, Amber Spangler, Sohail Rao, Luis L. Cantu, A. Krishna, Kathy Evans, Tylene Falkner, Brandi Kerr, R. Spees, Mailyn Marta, Amanda Harrington, R. Dolor, Madison Frazier, Lorraine Vergara, Jessica E. Wilson, Valencia Burruss, Teri Hurst, I. Ofotokun, Pauline Rebolledo, Rajesh Prabhu, K. Klicka, Amber Lightfeather, Vicki James, M. Rogers, Pradeep Parihar, De'Ambra Torress, Chukwuemeka Oragwu, Ngozi Oguego, Rajesh Pillai, Mustafa Juma, E. Ghaly, Dafer Al-Haddadin, C. Ramirez, Gammal Hassanien, S. Ismail, A. Meltzer, Seamus Moran, S. Brehaut, A. Roche, Manisha Mehta, Nicole Koppinger, J. Báez, I. Pagan, Dallal Abdelsayed, M. Aziz, Philip G. Robinson, Julie Nguyen, Victoria Pardue, Lisa D. Hammons, J. Ruiz-Unger, Susan A. Gonzalez, L. Reyes, J. Cienki, Gisselle A. Jimenez, Melvin H. L. Wong, Ying Yuan, Jenny Li, Jeremy Szeto, Lauren Stelmash, Daniel Haight, Deryl Lamb, Amron Harper, Nancy Pyram-Bernard, A. Quintero, E. Adhami, J. María, D. Paudel, Oksana Raymond, J. Summers, T. Turner, L. Lenert, Sam Gallegos, Elizabeth Szwast, Ahsan A. Abdulghani, Pravin Vasoya, Conrad Miller, Hawa Wiley, Nirav S. Shah, Tovah Klein, Julie Castex, Phillip Feliciano, Jacqueline Olivo, M. Ghaly, Zainub Javed, Alexandra Nawrocki, Anthony Vecchiarelli, Nikki Vigil, V. Cherukuri, Erica Burden, Dawn M Linn, L. Fisher, Vijay Patel, Praksha Patel, Yuti Patel, Leonard Ellison, Jeffrey Harrison, B. Shah, Sugata Shah, Upinder Singh, Julie M. Donahue, Yasmin Jazayeri, Anita Gupta, N. Chandrasekar, Beth Moritz, Tabitha Fortt, Anisa Fortt, Ingrid Jones-Ince, Alix McKee, Christy Schattinger, Jason Wilson, Brenda Farlow, Lillian Finlaw, Randall Richwine, Tearani Williams, Penny Paizer, L. Carson, E. Michelson, D. Austin, Sangeeta Khetpal, T. Cantrell, Drew Franklin, Karis Marshall, Arvind Mahadevan, M. Rosequist, M. Gnoni, Crystal Daffner, C. Vandeweerd, M. Roberts, Mark D'Andrea, Wayne Swink, Margaret V. Powers-Fletcher, Sylvere Mukunzi, Jamie Hensley, Brittney Manning, C. Isache, Jennifer Bowman, Angelique Callaghan-Brown, T. Scott, Tiffany Schwasinger-Schmidt, Ashlie Cornejo, Maria Almanzar, Letty Ginsburg, Americo Hajaz, C. Bramante, M. Robinson, M. Seithel, A. Sekikawa, Emily Klawson, L. Ostrosky, Virginia Umana, Thomas Patterson, Robin E Tragus, Patrick E H Jackson, C. Hallowell, H. Haughey, Bhavna Vaidya-Tank, C. Gould, P. Goyal, Carly Gatewood, John C. Williamson, Hannah M Seagle, Elizabeth L Salsgiver, E. Armas, Jhonsai Cheng, Priscilla Huerta, J. Garcia-Diaz, David Aamodt, JaMario Ayers, Jessica B. Collins, J. Graves, James Grindstaff, Jessica Lai, Itzel Lopez, Jessica S Marlin, Alyssa Merkel, S. Nwosu, Savannah Obregon, Dirk Orozco, Yoli Perez-Torres, Nelson Prato, Colleen Ratcliff, Max Rhode, J. Shirey-Rice, Krista K. Vermillion, Hsi-Nien Tan, Seibert Tregoning, Meghann Vance, Amber Vongsamphanh, M. Weir, Nicole M. Zaleski, S. Bozzette, Gene Passamani   +248 more
semanticscholar   +1 more source

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.

New England Journal of Medicine, 2022
BACKGROUND Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. METHODS In this phase 3, double-blind,
C. Bramante, J. Huling, C. Tignanelli, J. Buse, David M. Liebovitz, J. Nicklas, Kenneth Cohen, M. Puskarich, H. Belani, J. Proper, L. Siegel, N. Klatt, David J. Odde, Darlette G. Luke, Blake Anderson, Amy B Karger, N. Ingraham, K. Hartman, V. Rao, Aubrey A Hagen, Barkha P Patel, S. Fenno, N. Avula, Neha V. Reddy, S. M. Erickson, S. Lindberg, R. Fricton, Samuel Lee, A. Zaman, Hanna G Saveraid, Walker J Tordsen, M. Pullen, M. Biros, Nancy E. Sherwood, Jennifer L Thompson, D. Boulware, T. Murray   +36 more
semanticscholar   +1 more source

In vitro larvicidal activity of ivermectin and povidone-iodine against Oestrus ovis.

PLoS ONE, 2021
PurposeTo assess the in vitro larvicidal activity of ivermectin and povidone-iodine (PVP-I) against Oestrus ovis, the most frequent cause of external ophthalmomyiasis.MethodsL1 O.
Giuseppe D'Amico Ricci, Giovanni Garippa, Stefano Cortese, Rita Serra, Francesco Boscia, Stefano Dore, Antonio Pinna   +6 more
doaj   +2 more sources

Ivermectin for preventing and treating COVID‐19

Cochrane Database of Systematic Reviews, 2021
Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory ...
M. Popp, M. Stegemann, Maria-Inti Metzendorf, Susan Gould, P. Kranke, P. Meybohm, N. Skoetz, S. Weibel   +7 more
semanticscholar   +1 more source

Ivermectin metabolites reduce Anopheles survival

Scientific Reports, 2023
Ivermectin mass drug administration to humans or livestock is a potential vector control tool for malaria elimination. The mosquito-lethal effect of ivermectin in clinical trials exceeds that predicted from in vitro laboratory experiments, suggesting ...
Kevin C. Kobylinski, Phornpimon Tipthara, Narenrit Wamaket, Sittinont Chainarin, Rattawan Kullasakboonsri, Patchara Sriwichai, Siriporn Phasomkusolsil, Borimas Hanboonkunupakarn, Podjanee Jittamala, Renia Gemmell, John Boyle, Stephen Wrigley, Jonathan Steele, Nicholas J. White, Joel Tarning   +14 more
doaj   +1 more source

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.

JAMA Internal Medicine, 2022
Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed.
Steven Chee-Loon Lim, C. Hor, K. H. Tay, Anilawati Mat Jelani, Wen Hao Tan, H. Ker, T. S. Chow, M. Zaid, W. Cheah, H. Lim, K. Khalid, Joo Thye Cheng, Hazfadzila Mohd Unit, Noralfazita An, A. Nasruddin, L. L. Low, Song Weng Ryan Khoo, J. H. Loh, N. Zaidan, Suhaila Ab Wahab, Li Herng Song, H. M. Koh, T. King, N. Lai, S. Chidambaram, Kalaiarasu M. Peariasamy   +25 more
semanticscholar   +1 more source

Current therapeutic applications and pharmacokinetic modulations of ivermectin [PDF]

Veterinary World, 2019
Ivermectin is considered to be a wonder drug due to its broad-spectrum antiparasitic activity against both ectoparasites and endoparasites (under class of endectocide) and has multiple applications in both veterinary and human medicine.
Khan Sharun, T. S. Shyamkumar, V. A. Aneesha, Kuldeep Dhama, Abhijit Motiram Pawde , Amar Pal   +5 more
doaj   +1 more source

Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?

Epilepsia, 2023
There are only a few drugs that can seriously lay claim to the title of “wonder drug,” and ivermectin, the world's first endectocide and forerunner of a completely new class of antiparasitic agents, is among them.
W. Löscher
semanticscholar   +1 more source